Furthermore, we show that early- and late-stage administration of PKP2 gene therapy can be used as a means to circumvent and rescue ARVC development and mortality in this genetic PKP2 model that harbors patient genetics. Here, PKP2 is linked to Arrhythmogenic right ventricular dysplasia.